Pursuing the idea that the combination of RAD51 and PBRM1 might help define different ccRCC subtypes endowed with discordant prognosis and responses to immunotherapy, we assessed whether subtypes built on their status could stratify prognosis and the efficacy of ICB. The gene discussed is RAD51; the disease is nonpapillary renal cell carcinoma.